



Participants' perceived barriers to adherence vs.  
empirically-based barriers to adherence:  
Do they differ by age and race and ethnicity?

John A. Saucedo, PhD, MSc,  
Torsten B. Neilands, PhD, Mallory O. Johnson, PhD, & Parya Saberi, PharmD, MAS

Center for AIDS Prevention Studies (CAPS)  
University of California, San Francisco (UCSF)

# Background

#ADHERENCE2016




Race and ethnic disparities in ART adherence persist for variety of reasons.

Association between age and ART Adherence.

Disparities and depression w/non-adherence  
as a treatment interruption?

Barriers to ART adherence are extensively studied, yet little is known about barriers vary based on a person's age or race and ethnicity.



(Oh et al., 2009; Hinking et al., 2004; Simoni et al., 2012; Saucedo et al., 2016)



# Objective

We used an empirically-based analytic approach to examine the importance of barriers stratifying by age and race and ethnicity.

**Secondary hypothesis:** the most important barriers would be invariant across race/ethnicity and age subgroups (i.e., empirically)

# Brief Overview: Assessing Importance

#ADHERENCE2016




1. Dominance analysis is a class of Relative Important Analysis
  - Identify the “most important predictor(s) from a set of predictors.”
2. Problems with traditional regression approaches (short list)
  - A. Adherence barriers are correlated
  - B. Std. regression objective of “impact on Y per change in X” not ideal for “importance.”
  - C.  $R^2$  is influenced by order, other factors and model dependent
3. Advantage of dominance analysis
  - A. General pair-wise regression approach tests *all possible* barriers against one another.
  - B. Weight = *average squared semi-partial correlation* – i.e., each barrier in relation to the outcome of ART non-adherence.

# Interpreting Dominance Weights and Patterns

#ADHERENCE2016



1. Does one barrier *consistency outperform* other barriers in predicting ART non-adherence?



<b>General (Least dominant)</b>	<b>Conditional (Somewhat dominant)</b>	<b>Complete (Most dominant)</b>
<i>Based on every possible comparison</i>		
<u>Average variance</u> contributed by one barrier is greater than the <u>average variance</u> contributed by another barrier	<u>Average variance</u> contributed by one barrier is greater in size than any one contribution of another barrier	Amount of <u>additional variance</u> one barrier has singularly contributed is greater than any amount of variance contributed by any other barrier


# Demographics

#ADHERENCE2016



## •Sample Characteristics

- Mean age was **46.7** (SD = 10.9, Median = 48)
- **44%** reported a college-level education
- **57%** reported annual income of less than \$40,000
- **76.3%** self-identified as non-Latino White



## HIV and ART Adherence-related Information

- **13%** reported a detectable VL
- **69.8%** reported once-daily dosed ART
- **28.8%** twice-daily dosed ART
- **14%** reported at least one, 4-day Tx interruption in past 3 months

# Sample Characteristics

#ADHERENCE2016



## Dominance Analyses

1. Stratified analysis by selecting out race/ethnic groups from total sample:
  - a. Non-Latino Whites,  $n = 929$
  - b. Latinos,  $n = 154$
  - c. African Americans,  $n = 110$
2. Stratified analysis by selecting out age subgroups from total sample:
  - a. Young adults (18-29 years),  $n = 104$
  - b. Middle-aged adults (30-49 years),  $n = 590$
  - c. Older adults ( $> 50$  years),  $n = 524$



# Results: Comparisons by Race and Ethnicity and Age

*Dominance analysis ranking by race and ethnicity*

<b>Non-Latino White (n=929)</b>		<b>Latinos (n=148)</b>		<b>African Americans (n=110)</b>	
Adherence Barrier	Dominance Weights	Adherence Barrier	Dominance Weights	Adherence Barrier	Dominance Weights
#1 Day-to-day life	.290	#1 Asleep/slept through dose time	.288	#1 Alcohol or using illicit drugs	.521
#2 Asleep/slept through dose time	.178	#2 Day-to-day life	.237	#2 Felt sick or ill	.183
#3 Problems with pharmacy/insurance	.163	#3 Ran out of pills	.151	#3 Simply forgot	.081
#4 Simply forgot	.157	#4 Simply forgot	.142	#4 Wanted to avoid side-effects	.066
#5 Felt depressed/overwhelmed	.152	#5 Alcohol or using illicit drugs	.067	#5 Felt depressed/overwhelmed	.051
#6 Alcohol or using illicit drugs	.038	#6 Problems with pharmacy/insurance	.062	#6 Day-to-day life	.050
#7 Felt sick or ill	.011	#7 Felt sick or ill	.034	#7 Asleep/slept through dose time	.030
#8 Wanted to avoid side-effects	.006	#8 Felt depressed/overwhelmed	.020	#8 Problems with pharmacy/insurance	.011
#9 Ran out of pills	.004	#9 Wanted to avoid side-effects	.000	#9 Ran out of pills	.007

*Dominance analysis rankings by Age*

<b>Young Adults (n=104) 18-29 yrs</b>		<b>Middle-aged Adults (n=590) 30-49 yrs.</b>		<b>Older Adults (n=524) &gt;50 yrs.</b>	
Adherence Barrier	Dominance Weights	Adherence Barrier	Dominance Weights	Adherence Barrier	Dominance Weights
#1 Alcohol or using illicit drugs	.521	#1 Felt depressed/overwhelmed	.454	#1 Asleep/slept through dose time	.580
#2 Felt sick or ill	.183	#2 Day-to-day life	.187	#2 Problems with pharmacy/insurance	.230
#3 Simply forgot	.081	#3 Alcohol or using illicit drugs	.119	#3 Alcohol or using illicit drugs	.057
#4 Wanted to avoid side-effects	.066	#4 Wanted to avoid side-effects	.096	#4 Wanted to avoid side-effects	.042
#5 Felt depressed/overwhelmed	.051	#5 Problems with pharmacy/insurance	.077	#5 Felt depressed/overwhelmed	.040
#6 Day-to-day life	.050	#6 Asleep/slept through dose time	.027	#6 Simply forgot	.033
#7 Asleep/slept through dose time	.030	#7 Ran out of pills	.021	#7 Day-to-day life	.015
#8 Problems with pharmacy/insurance	.011	#8 Felt sick or ill	.020	#8 Ran out of pills	.007
#9 Ran out of pills	.007	#9 Simply forgot	.008	#9 Felt sick or ill	.004

# Discussion: Race and Ethnicity

#ADHERENCE2016



1. Stratified dominance analyses showed that **no one barrier to adherence** was most important to all groups.
  - Similar patterns did emerge.
2. Non-Latino White and Latino subgroups were most similar.
  - “**Day-to-day life**” and “**Fell asleep/slept through dose**” barriers were two most important for these groups.
3. African American subgroup had different pattern of results.
  - “**Alcohol & drugs**” yielded largest dominance weight (.521).
  - “**Felt sick or ill**” yielded second largest weight (.183).

# Discussion: Age

#ADHERENCE2016



## 6. Young Adults:

- #1 ranked barrier = “**Drinking alcohol or using illicit drugs**” (.521).
- Also ranked #3 for middle-age and older adult subgroups.

## 7. Middle-aged adult subgroup:

- #1 ranked barrier = “**Felt depressed/overwhelmed**” (.454).
- More important vs. other age subgroups.

## 8. Older adult subgroup:

- #1 ranked barrier = “**Fell asleep/slept through dose**” (.580).

10. “**Drinking alcohol or using illicit drugs**” and “**wanted to avoid side-effects**” barriers was most consistent across age subgroups.



# Implications

- Examine how barriers to adherence express themselves and vary based on the target population characteristics.
  - Younger versus older-aged groups experiences with HIV.

*It is important to address those barriers that are most strongly linked to clinical outcomes and not necessarily those that are most frequently reported.*



# Limitations

1. All data were self-reported.
  - No incentives to participate were provided & the direction of the effect of interest was predicting non-adherence.
2. A replication study is needed to support the stability of weights.
  - Statistical power is not directly related to dominance analysis because it is not a null hypothesis significance test.
3. Total sample consisted of mostly college educated and gay-identified men with access to online social media.
4. We could not determine conclusively the chronological order of effect for a treatment interruption on an HIV VL outcome.



# Limitations – Study Two

1. Stratified analyses were for exploratory purposes.
2. A replication study is needed to support the stability of weights.
  - Each stratified dominance analysis consisted of smaller and restrictive sample.
  - Age groups were selected arbitrarily.

# Acknowledgement

#ADHERENCE2016



- **All participants and research staff at UCSF**
- **Co-authors and Mentors**
  - Mallory O. Johnson, PhD
  - Torsten B. Neilands, PhD
  - Parya Saberi, PharmD, MAS
- **Funding Source**
  - NIMH and NIDA
  - T32 MH19105 (PI: Kegeles, S)
  - K23 MH097649 (PI : Saberi, P. )
  - K24 DA037034 & R01 MH102198 (PI : Johnson, M).



# Questions?

Email: [john.sauceda@ucsf.edu](mailto:john.sauceda@ucsf.edu)

